HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile

Infectious Agents and Cancer

Volumn 10, Issue 1, 2015, Pages

  Lagos, Marcela ^a   Van De Wyngard, Vanessa ^b   Poggi, Helena ^a   Cook, Paz ^b   Viviani, Paola ^b   Barriga, María Isabel ^b   Pruyas, Martha ^c   Ferreccio, Catterina ^b,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^d University of Chile   (Chile)

Author keywords

Cervical cancer screening; Genotype; HPV 16; HPV 18; HPV DNA testing; Human papillomavirus; Triage

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; CHILE; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

EID: 84947910399     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/s13027-015-0038-5     Document Type: Article

References (20)

1. Chile Ministry of Health, Departamento de Estadisticas e Informacion de Salud. http://www.deis.cl/wp-content/uploads/2012/11/CoberturaPAP-Oficial-Region2010-2011.pdf (in Spanish; accessed 17 October 2014).
2. Chile Ministry of Health, Departamento de Estadisticas e Informacion de Salud. http://deis.minsal.cl/vitales/vitales2010/Serie-Mortalidad-causa-Chile-2000-2010/Chile.htm (in Spanish; accessed 17 October 2014).
3. Ferreccio C, Barriga MI, Lagos M, Ibanez C, Poggi H, Gonzalez F, et al. Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. Int J Cancer. 2013;132(4):916-23.
4. Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30S:F88-99.
5. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524-32.
6. de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-56.
7. Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927-35.
8. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice. J Natl Cancer Inst. 2005;97:1072-9.
9. Bulk S, Bulkmans NWJ, Berkhof J, Rozendaal L, Boeke AJP, Verheijen RHM, et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer. 2007;121:361-7.
10. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of Persistence. J Natl Cancer Inst. 2010;102:1478-88.
11. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Brit J Cancer. 2003;89:101-5.
12. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer. 2007;121:621-32.
13. Benoy IH, Broeck DV, Ruymbeke MJ, Sahebali S, Arbyn M, Bogers JJ, et al. Prior knowledge of HPV status improves detection of CIN2 by cytology screening. Am J Obstet Gynecol. 2011;205:569.e1-7.
14. Wright TC, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206:46.e1-11.
15. Ili CG, Brebi P, Lopez J, Garcia P, Leal P, Suarez E, et al. Genotyping of Human papillomavirus in Cervical Intraepithelial Neoplasia in a High-Risk Population. J Med Virol. 2011;83:833-7.
16. Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12:880-90.
17. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VMH, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer. 2012;130:602-10.
18. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening. J Natl Cancer Inst. 2009;101:88-99.
19. Castle PE, Lorincz AT, Mielzynska-Lohnas I, Scott DR, Glass AG, Sherman ME, et al. Results of Human Papillomavirus DNA Testing with the Hybrid Capture 2 Assay Are Reproducible. J Clin Microbiol. 2002;40:1088-90.
20. Godinez JM, Tous S, Baixeras N, Moreno-Crespi J, Alejo M, Lejeune M, et al. Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array. Infect Agents Canc. 2011;6:23.